Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of MAP0004 in Adult Migraineurs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~* Male or female between 18 and 65 years of age.~* History of episodic, acute migraine (with or without aura) with onset prior to 50~Major Exclusion Criteria:~* Known allergy or sensitivity or contraindication to study drugs or their formulations~* History of chronic pulmonary disease, coronary artery disease (CAD), liver disease, kidney disease, seizures, stroke, or major psychiatric condition.~* Any condition that, in the opinion of the Investigator, would make the subject unsuitable for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MAP0004 (Type: EXPERIMENTAL): MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks.
- Placebo (Type: OTHER): Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).